Current palliative pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis led to the development of four cholinesterase inhibitors. These compounds can bring prolongation of the symptom-free period in some patients. This is the first report directly comparing donepezil and rivastigmine plasma and brain levels in in-vivo study. Donepezil and rivastigmine were applied i.m. to rats; the dose was calculated from clinical recommendations. The samples were analysed on an Agilent 1260 Series LC with UV/VIS detector. An analytical column (Waters Spherisorb S5 W (250 mm × 4.6 i.d.; 5 μm particle size)) with guard column (Waters Spherisorb S5 W (30 mm × 4.6 mm i.d.)) was used. The mobile phase contained acetonitrile and 50 mM sodium dihydrogen phosphate (17:83; v/v); pH 3.1. The LLOQ in rat plasma was 0.5 ng/mL for donepezil and 0.8 ng/mL for rivastigmine, and the LLOQ in rat brain was 1.0 ng/mL for donepezil and 1.1 ng/mL for rivastigmine. Both compounds showed ability to target the central nervous system, with brain concentrations exceeding those in plasma. Maximum brain concentration after i.m. administration was reached in the 36 (8.34 ± 0.34 ng/mL) and 17 minute (6.18 ± 0.40 ng/mL), respectively for donepezil and rivastigmine. The differences in brain profile can be most easily expressed by plasma/brain AUCtotal ratios: donepezil ratio in the brain was nine-times higher than in plasma and rivastigmine ratio was less than two-times higher than in plasma.

Biomedical Research Centre University Hospital Hradec Kralove Czech Republic

Department of Chemistry Faculty of Science University of Hradec Kralove Hradec Kralove Czech Republic

Department of Toxicology and Military Pharmacy Faculty of Military Health Sciences University of Defence Hradec Kralove Czech Republic

Zobrazit více v PubMed

Basiri A, Xiao M, McCarthy A, Dutta D, Byrareddy SN, Conda-Sheridan M. Design and synthesis of new piperidone grafted acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. . 2017;27:228–31. PubMed PMC

Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer disease. Lancet . 1967;2:1403. PubMed

Ballatore C, Lee VMY, Trojanowski JQ. Tau-Mediated Neurodegeneration in Alzheimer’s disease and related disorders. Nat. Rev. Neurosci. . 2007;8:663–72. PubMed

Geldenhuys WJ, Darvesh AS. Pharmacotherapy of Alzheimer’s disease: current and future trends. Expert Rev. Neurother. . 2015;15:3–5. PubMed

Castellani RJ, Rolston RK, Smith MA. Alzheimer Disease. Dis. Mon. . 2010;56:484–546. PubMed PMC

Sugimoto H, Yamanishi Y, Iimura Y, Kawakami Y. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr. Med. Chem. . 2000;7:303–39. PubMed

Valis M, Masopust J, Vysata O, Hort J, Dolezal R, Tomek J, Misik J, Kuca K, Karasova JZ. Concentration of donepezil in the cerebrospinal fluid of ad patients: evaluation of dosage sufficiency in standard treatment strategy. Neurotox. Res. . 2017;31:162–8. PubMed PMC

Chen X, Magnotta VA, Duff K, Boles-Punto LL, Schultz SK. Donepezil effects on cerebral blood flow in older adults with mild cognitive deficits. J. Neuropsychiatry Clin. Neurosci. . 2006;18:178–85. PubMed

Tsukada H, Sato K, Kakiuchi T, Nishiyama S. Age-related impairment of coupling mechanism between neuronal activation and functional cerebral blood flow response was restored by cholinesterase inhibition: PET study with microdialysis in the awake monkey brain. Brain Res. . 2000;857:158–64. PubMed

Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy . 2000;20:1–12. PubMed

Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, Lee B, Ingram DK, Lahiri DK. A new therapeutic target in Alzheimer’s disease treatment: Attention to butyrylcholinesterase. Curr. Med. Res. . 2001;17:159–65. PubMed

Ballard CG. Advances in the treatment of Alzheimer’s disease: Benefits of dual cholinesterase inhibition. Eur. Neurol. . 2002;47:64–70. PubMed

Amini H, Ahmadiani A. High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies. Iran J. Pharm. Res. . 2010;9:115–21. PubMed PMC

Karasova JZ, Hroch M, Musilek K, Kuca K. Small quaternary inhibitors K298 and K524: Cholinesterases inhibition, absorption, brain distribution, and toxicity. Neurotox. Res. . 2016;29:267–74. PubMed

Karasova JZ, Zemek F, Musilek K, Kuca K. Time-dependent changes of oxime K027 concentrations in different parts of rat central nervous system. Neurotox. Res. . 2013;23:63–8. PubMed

Giacobini E. Cholinesterase inhibitors: new role and therapeutic alternatives. Pharm. Res. . 2004;50:433–40. PubMed

Seltzer B. Donepezil: a review. Expert Opin. Drug Met. . 2005;1:527–36. PubMed

Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br. J. Clin. Pharmacol. . 1998;46 (Suppl 1):13–8. PubMed PMC

Darreh-Shori T, Meurling L, Pettersson T, Hugosson K, Hellstrom-Lindahl E, Andreasen N, Minthon L, Nordberg A. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer’s disease following chronic donepezil treatment. J. Neural. Transm. . 2006;113:1791–801. PubMed

Jelic V, Darreh-Shori T. Donepezil: A review of pharmacological characteristics and role in the management of Alzheimer disease. Clin. Med. Insights Ther. . 2010;2:771–88.

Geerts H, Guillaumat PO, Grantham C, Bode W, Anciaux K, Sachak S. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res. . 2005;1033:186–93. PubMed

Darreh-Shori T, Almkvist O, Guan ZZ, Garlind A, Strandberg B, Svensson AL, Soreq H, Hellstrom-Lindahl E, Nordberg A. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology . 2002;59:563–72. PubMed

Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer’s disease by rivastigmine: correlation with cognitive benefit. J. Neural. Transm. . 2002;109:1053–65. PubMed

Mzik M, Korabecny J, Nepovimova E, Vorisek V, Palicka V, Kuca K, Karasova JZ. An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC-48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. J. Chromatogr. B . 2016;1020:85–9. PubMed

Karasova JZ, Mzik M, Hroch M, Korabecny J, Nepovimova E, Vorisek V, Palicka V, Kuca K. The new acetylcholinesterase Inhibitors PC-37 and PC-48 (7-methoxytacrine-donepezil-like compounds): Characterization of their metabolites in human liver microsomes, pharmacokinetics and in-vivo formation of the major metabolites in rats. Bas. Clin. Pharm. Toxicol . 2018;122:373–82. PubMed

Karasova JZ, Sestak V, Korabecny J, Mezeiova E, Palicka V, Kuca K, Mzik M. 1-Benzyl-4-methylpiperidinyl moiety in donepezil: The priority ticket across the blood-brain-barrier in rats. J.Chromatogr. B . 2018;1092:350–8. PubMed

Sadowsky CH, Micca JL, Grossberg GT, Velting DM. Rivastigmine from capsules to patch: Therapeutic advances in the management of Alzheimer’s disease and Parkinson’s disease dementia. Prim. Care Companion CNS Disord. . 2014;16 PubMed PMC

Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab. Rev. . 2009;41:67–76. PubMed

Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-(11C)verapamil and positron emission tomography. Clin. Pharmacol. Ther. . 2006;79:540–8. PubMed

Bartels AL, Kortekaas R, Bart J, Willemsen AT, de Klerk OL, de Vries JJ, van Oostrom JC, Leenders KL. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol. Aging . 2009;30:1818–24. PubMed

Goh CW, Aw CC, Lee JH, Chen CP, Browne ER. Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young lister hooded rats. Drug Metab. Dispos. . 2011;39:402–11. PubMed